A Chemogenomic Analysis of the Human Proteome: Application to Enzyme Families

Sequence-based phylogenies (SBP) are well-established tools for describing relationships between proteins. They have been used extensively to predict the behavior and sensitivity toward inhibitors of enzymes within a family. The utility of this approach diminishes when comparing proteins with little sequence homology. Even within an enzyme family, SBPs must be complemented by an orthogonal method that is independent of sequence to better predict enzymatic behavior. A chemogenomic approach is demonstrated here that uses the inhibition profile of a 130,000 diverse molecule library to uncover relationships within a set of enzymes. The profile is used to construct a semimetric additive distance matrix. This matrix, in turn, defines a sequence-independent phylogeny (SIP). The method was applied to 97 enzymes (kinases, proteases, and phosphatases). SIP does not use structural information from the molecules used for establishing the profile, thus providing a more heuristic method than the current approaches, which require knowledge of the specific inhibitor's structure. Within enzyme families, SIP shows a good overall correlation with SBP. More interestingly, SIP uncovers distances within families that are not recognizable by sequence-based methods. In addition, SIP allows the determination of distance between enzymes with no sequence homology, thus uncovering novel relationships not predicted by SBP. This chemogenomic approach, used in conjunction with SBP, should prove to be a powerful tool for choosing target combinations for drug discovery programs as well as for guiding the selection of profiling and liability targets. (Journal of Biomolecular Screening 2007:972-982)

[1]  Shoshana D. Brown,et al.  A gold standard set of mechanistically diverse enzyme superfamilies , 2006, Genome Biology.

[2]  C.-Y. Tsai,et al.  A purchase-based market segmentation methodology , 2004, Expert Syst. Appl..

[3]  W. Lamboy,et al.  Computing genetic similarity coefficients from RAPD data: the effects of PCR artifacts. , 1994, PCR methods and applications.

[4]  Irwin D Kuntz,et al.  Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. , 2002, Chemistry & biology.

[5]  Philip M Dean,et al.  Probes for chemical genomics by design. , 2002, Drug discovery today.

[6]  P. B. Chock,et al.  Regulation of PTP1B via glutathionylation of the active site cysteine 215. , 1999, Biochemistry.

[7]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[8]  J. Ermolieff,et al.  Protein tyrosine phosphatase 1B inhibitors for diabetes , 2002, Nature Reviews Drug Discovery.

[9]  P. Marynen,et al.  Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.

[10]  R. Reid,et al.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Satchidananda Panda,et al.  An array of insights: application of DNA chip technology in the study of cell biology. , 2003, Trends in cell biology.

[12]  P. Babbitt.  Definitions of enzyme function for the structural genomics era. , 2003, Current opinion in chemical biology.

[13]  M. Murcko,et al.  Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.

[14]  Ruedi Stoop,et al.  An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..

[15]  James R. Knight,et al.  A Protein Interaction Map of Drosophila melanogaster , 2003, Science.

[16]  M. Vieth,et al.  Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.

[17]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[18]  H. Rüdiger,et al.  [Contribution to population genetics of pyruvate kinase from human erythrocytes. ATP-pyruvate phosphotransferase, E.C.2.7.1.40]. , 1968, Humangenetik.

[19]  C. Hodge,et al.  Discovery of highly selective inhibitors of p38α , 2005 .

[20]  G. Bemis,et al.  The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.

[21]  Jonathan Bingham,et al.  Visualizing large hierarchical clusters in hyperbolic space , 2000, Bioinform..

[22]  Chung-Horng Lung,et al.  Applications of clustering techniques to software partitioning, recovery and restructuring , 2004, J. Syst. Softw..

[23]  Brent R Stockwell,et al.  Advances in chemical genetics. , 2005, Annual review of genomics and human genetics.

[24]  J. Felsenstein.  An alternating least squares approach to inferring phylogenies from pairwise distances. , 1997, Systematic biology.

[25]  Lawrence P. Wackett,et al.  Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different , 2001, Journal of bacteriology.

[26]  M. Vieth,et al.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.

[27]  S. Frye.  Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[28]  A. Gorse.  Diversity in medicinal chemistry space. , 2006, Current topics in medicinal chemistry.

[29]  William P Janzen,et al.  A Chemogenomic Approach to Discovering Target‐Selective Drugs , 2006, Chemical biology & drug design.

[30]  Joseph Felsenstein,et al.  Alternative Methods of Phylogenetic Inference and their Interrelationship , 1979 .